samedan logo

 
 
spacer
home > ict > spring 2019 > a three-pronged strategy
PUBLICATIONS
International Clinical Trials

A Three-Pronged Strategy

Information on clinical trials is made available to the public on more than 30 clinical trial registries, including ClinicalTrials.gov and the EU Clinical Trials Register (EU CTR). In theory, these registries allow patients to find clinical trials they might consider joining and to review the results of completed research.However, because the information is presented in a format intended primarily for researchers and healthcare professionals, patients and caregivers often become disengaged and discouraged. Compounding this issue, trial information and availability are inconsistent across registries and highly variable among trial sponsors, with important data such as clinical trial results often simply missing.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As Trialscope’s Chief Strategy Officer, Thomas Wicks is responsible for the strategy of clinical trial disclosure and transparency solutions. He has more than 20 years of experience with performance and content management solutions, specialising in applications for life sciences such as clinical trial disclosure, structured product labelling, and submissions management. He has been focused on trial transparency since 2007.
spacer
Thomas Wicks
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Distributor Oppurtunities

Have an appetite for success – Want to expand your product portfolio – Fancy being part of something special??
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology

27 August - 21 November 2019, Barcelona, Spain

On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement